Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22805424 | 1.00 | BCDIN3D (1.00) | BCDIN3DSHMT2 | |
| SCHEMBL13947042 | 0.90 | BCDIN3D (0.82) | BCDIN3DSHMT2 | |
| SCHEMBL13943303 | 0.89 | BCDIN3D (0.81) | BCDIN3DSHMT2 | |
| SCHEMBL13943296 | 0.88 | BCDIN3D (0.79) | BCDIN3DSHMT2 | |
| SCHEMBL13943317 | 0.88 | BCDIN3D (0.78) | BCDIN3DSHMT2 | |
| SCHEMBL13943304 | 0.88 | BCDIN3D (0.78) | BCDIN3DSHMT2 | |
| SCHEMBL22806010 | 0.85 | BCDIN3D (1.00) | BCDIN3DSHMT2 | |
| SCHEMBL29582423 | 0.85 | BCDIN3D (1.00) | BCDIN3DSHMT2 | |
| SCHEMBL22805563 | 0.85 | BCDIN3D (1.00) | BCDIN3D | |
| SCHEMBL22806295 | 0.85 | BCDIN3D (1.00) | BCDIN3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986568-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY | Storm Therapeutics Ltd (GB) | 2022-04-27 | — | — | EP | claimed |
| US-20220370453-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BCDIN3D ACTIVITY | STORM THERAPEUTICS LIMITED (GB) | 2022-11-24 | — | — | US | disclosed |
| EP-3986568-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY | Storm Therapeutics Ltd (GB) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370453-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BCDIN3D ACTIVITY | BCDIN3D, CDK3, CCNI | BCDIN3D 1/4885SHMT2 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.